<DOC>
	<DOCNO>NCT01786382</DOCNO>
	<brief_summary>The primary objective study : - Evaluate potential effect PPI-668 steady state pharmacokinetic ( PK ) profile midazolam follow single oral dose human subject . - Evaluate potential effect PPI-668 steady state PK profile omeprazole follow single oral dose human subject</brief_summary>
	<brief_title>A Drug Interaction Study Effects PPI-668 Pharmacokinetics Midazolam Omeprazole</brief_title>
	<detailed_description />
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>1 . Subject legally authorize representative sign Institutional Review Board ( IRB ) approve write informed consent privacy language per national regulation ( e.g. , Health Insurance Portability Accountability Act [ HIPAA ] authorization site United States ) studyrelated procedure ( include withdrawal prohibit medication , applicable ) perform 2 . Age 18 50 year 3 . Body mass index ( BMI ) 1832 kg/m2 4 . Clinical laboratory finding consistent good health opinion investigator 5 . Women nonchildbearing potential men agree utilize adequate contraception throughout study 1 . Women nonchildbearing potential must one following : Postmenopausal ( &gt; 2 year amenorrhea postmenopausal status confirm folliclestimulating hormone level ) Surgically sterile ( documentation prior tubal ligation , hysterectomy , oophorectomy require ) 2 . Male subject surgically sterile must agree use one follow birth control method sexually active : Doublebarrier contraceptive ( e.g. , condom plus diaphragm , condom diaphragm spermicidal gel/foam ) Female partner least two year postmenopausal surgically sterile 1 . Positive result follow test Screening Day 1 : urine pregnancy ( woman ) , urine drug abuse alcohol , hepatitis B surface antigen , hepatitis C antibody , human immunodeficiency virus antibody 2 . Concurrent clinically significant medical diagnosis would potentially interfere subject 's study compliance confound study result 3 . Concurrent social condition ( e.g. , drug alcohol abuse , transportation difficulty ) would potentially interfere subject 's study compliance 4 . Clinically significant illness within 30 day precede entry study 5 . Participation investigational drug study within 30 day 5 halflives , whichever longer , Screening 6 . Use prescription medication within 14 day Day 1 throughout study . ( The use nonprescription overthecounter medication prohibit within 7 day Day 1 throughout study . This include herbal supplement remedy vitamin . )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>